Navigation Links
ULURU Inc. Announces Completion Of $2.2mil Convertible Debt Offering
Date:7/3/2012

ADDISON, Texas, July 3, 2012 /PRNewswire/ -- ULURU Inc. (OTCQB: ULUR), a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products, today announced it has completed a $2.2mil secured convertible debt financing with Inter-Mountain Capital Corp ("Inter-Mountain"). Proceeds from the convertible debt will be received in seven tranches with the initial tranche being $710,000 and six subsequent tranches of $250,000. The Company intends to use the funds for general corporate purposes.

At the option of Inter-Mountain, the outstanding principal balance of the convertible note may be converted into shares of ULURU Inc. common stock at a conversion price of $0.35 per share, subject to certain pricing adjustments and ownership limitations. The note is for a term of 33 months, with monthly instalment payments of $83,333 commencing no earlier than September 27, 2012. The convertible note will bear interest at the rate of 8.0% per annum. At ULURU's option, the monthly installment may be paid in whole, or in part, in cash or in Uluru Common Stock. If the monthly installment is paid in ULURU Common Stock, the shares will be issued at a 20% discount. At the option of ULURU, the outstanding principal balance of the convertible note, or a portion thereof, may be prepaid. The convertible note is secured by the grant to Inter-Mountain of a priority security interest in the assets of the Company.

As part of the convertible debt financing, Inter-Mountain will also receive warrants to purchase up to an aggregate of 3,142,857 shares of ULURU Common Stock. The warrants have an exercise price of $0.35 per share, and are exercisable, subject to vesting provisions and ownership limitations, until June 27, 2017.

Commenting on the financing, Kerry P. Gray, President and CEO of ULURU, stated, "We are very pleased to have completed this financing as it provides us with the resources to introduce Altrazeal® in numerous international markets. We continue to be very excited with the international opportunity for Altrazeal®. The clinical results that have been generated, in both Europe and Australia, clearly demonstrate the economic benefits that Altrazeal® can achieve."

As part of the convertible debt financing, Uluru entered into a Registration Rights Agreement whereby ULURU will prepare and file with the Securities and Exchange Commission a registration statement no later than July 27, 2012, for the registration 2.3 million shares and cause such registration statement to be declared effective no later than ninety days after such filing.

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex® Aggregate technology and OraDisc™ transmucosal delivery system. For further information about ULURU Inc., please visit our website at www.ULURUinc.com. For further information about Altrazeal®, please visit www.Altrazeal.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended. These statements are subject to numerous risks and uncertainties, including but not limited to the clinical and economic benefit and international potential of Altrazeal® and the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2011, and other reports filed by us with the Securities and Exchange Commission.

Contact: Company
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
(214) 905-5145

 


'/>"/>
SOURCE ULURU Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Omeros Announces Closing of $34.5 Million Public Offering of Common Stock
2. Amylin Pharmaceuticals, Inc. Shareholder Alert: Bernstein Liebhard LLP Announces Investigation Of Acquisition By Bristol-Myers Squibb Company
3. MicroVention Announces First Patient Enrollment In Clinical Trial To Compare Coiling Technologies For Treating Brain Aneurysms
4. Omron Healthcare Announces New Pedometers
5. Improved Maintenance and Control of Electronic Health Records. ICAP Patent Brokerage Announces for Auction Patented Techniques for Improved Patient Control and Selective Access to Electronic Medical Records
6. Lilly Diabetes Announces Once Upon A Time Contest Winner
7. Roche announces FDA approval of HIV viral load test
8. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Amylin Pharmaceuticals, Inc.
9. K-V Pharmaceutical Company Announces Notification from NYSE Regarding Listing Criteria
10. Talyst Announces AutoSplit Contract Pharmacy at 340B Coalition
11. KALO Announces Distribution Areas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... March 24, 2017 According to a new report published ... Industry Forecast, 2014-2022," the spine bone stimulators market was valued at $562 million ... a CAGR of 3.6% during the forecast period. ... ... Logo ...
(Date:3/24/2017)... 24, 2017 Research and Markets has announced the ... report to their offering. ... This report analyzes the worldwide markets for Dental Implants in US$ Million. ... , Japan , Europe , ... Rest of World. Annual estimates and forecasts are provided ...
(Date:3/24/2017)... Research and Markets has announced the addition of ... to their offering. ... IPF pipeline is very strong with a total of 97 drug candidates. ... and Sanofi are involved in the development of the IPF therapeutics. The ... Phase III stage, 15 are in Phase II stage, 12 are in ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... In ... innovative EcoQube Frame vertical micro-veggies garden on Kickstarter . Surpassing the $100,000 ... – with nearly 2,000 consumers (and counting) already backing the campaign. , ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... panels at the Advanced ERISA Benefit Claims Litigation seminar in Chicago, Illinois. ... Administrative Record, The majority of cases litigated under ERISA involve claims for long-term ...
(Date:3/24/2017)... Miami, FL (PRWEB) , ... March 24, 2017 ... ... HyGIeaCare Inc. ( http://www.hygieacare.com ) announced their partnership to prep patients for colonoscopy ... Health Endoscopy Centers in 87th Ave., Miami, FL. , The ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... to Walk with God #TruthwithGrace”: a devotional journal chronicling the writer’s path toward ... Learning How to Walk with God #TruthwithGrace” is the creation of published author ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... collection of inspiring stories about real people of God in congregations across the ... John Miller, a Presbyterian minister ordained in 1964 who has served congregations in ...
Breaking Medicine News(10 mins):